Crispr Therapeutics AG's total assets for Q3 2025 were $2.25B, an increase of 10.62% from the previous quarter. CRSP total liabilities were $329.33M for the fiscal quarter, a 3.37% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.